Protein– tag –
-
BeOne Medicines’ BEQALZI™ (Sonrotoclax) Gains US FDA Approval for Relapsed/Refractory Mantle Cell Lymphoma as First BCL2 Inhibitor
Stock Titan USA Overview BeOne Medicines announced that BEQALZI™ (sonrotoclax) has received U.S. FDA approval for the treatment of relapsed/refractory Mantle Cell Lymphoma (MCL), marking it as the first BCL2 inhibitor for this indication... -
Samsung Biologics Labor Dispute Stalls Wage Talks, Raising Concerns for Global CDMO Competitiveness
The Elec Inc. South Korea Overview Wage negotiations between management and labor union at Samsung Biologics have reached a prolonged stalemate, raising concerns about the company's global competitiveness in the Contract Development and ... -
Polpharma Biologics and Tuteur Forge Alliance to Boost Biosimilar Access Across Latin America
Morningstar ポーランド Overview Polpharma Biologics has finalized a strategic licensing agreement with Argentina's Tuteur Pharmaceutical, granting exclusive commercialization rights for a biosimilar targeting autoimmune diseases across L... -
Thousand Oaks Biologics Honored with Forbes China Industry Award for Leading ADC CDMO Capabilities
TMX Newsfile China Overview Thousand Oaks Biologics has been awarded the "2026 Forbes China Industry Development Leading Enterprise Award" for its advanced capabilities in antibody-drug conjugate (ADC) manufacturing. Operating across Chi... -
Wave Life Sciences Reports Positive RNA Editing Clinical Data for WVE-006 in Alpha-1 Antitrypsin Deficiency (AATD)
BioPharm International USA Overview Wave Life Sciences announced favorable clinical data from the RestorAATion-2 trial of WVE-006, an RNA editing therapeutic for Alpha-1 Antitrypsin Deficiency (AATD). WVE-006, a GalNAc-conjugated RNA edi... -
Eli Lilly Acquires Engage Biologics for Up to $202 Million to Strengthen Non-Viral DNA Delivery Platform
GuruFocus USA Overview Eli Lilly has agreed to acquire Engage Biologics for up to $202 million, aiming to leverage Engage’s innovative non-viral DNA delivery platform and accelerate the development of next-generation gene therapies. Enga... -
Isomorphic Labs Secures $2.1 Billion to Scale AI Drug Discovery Engine, Eyes First AI-Designed Drug in Human Trials by Year-End
AI Healthcare News USA Overview Isomorphic Labs, Alphabet's AI drug discovery arm, has raised a staggering $2.1 billion to expand its "IsoDDE" AI engine. Leveraging AI in conjunction with AlphaFold 3, the company develops a platform to p... -
Electrochemical Biosensors Redefine Cancer Biomarker Detection: From Molecular Sensing to Clinical Translation
MDPI Biosensors Switzerland Overview Electrochemical biosensors are emerging as powerful tools for early cancer biomarker detection. This review focuses on their application in detecting protein biomarkers (CEA, PSA, CRP), nucleic acid m... -
Nanoengineered Electrochemical Biosensors Emerge as Next-Gen Technology for Ultrasensitive Cancer Biomarker Detection
Nanoscale (RSC Publishing) UK Overview Nanoengineered electrochemical biosensors are poised to be the next generation in early cancer detection. By integrating diverse DNA, RNA, and protein-based biomarkers, these sensors significantly e... -
Biosensors for Heavy Metal Detection in Water: Rapid, On-Site Monitoring for Environmental Quality
IntechOpen UK Overview Biosensors offer a simple, reliable, and rapid solution for monitoring heavy metal contamination in water. Applicable to food production water and wastewater, these miniaturized devices eliminate the need for costl...
